A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

Joshi Alumkal, Rachel Slottke, Jacob Schwartzman, Ganesh Cherala, Myrna Munar, Julie Graff, Tomasz (Tom) Beer, Christopher Ryan, Dennis Koop, Angela Gibbs, Lina Gao, Jason F. Flamiatos, Erin Tucker, Richard Kleinschmidt, Motomi (Tomi) Mori

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Introduction: Diets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets also demonstrate modulation of gene expression in important pathways in prostate cells. Purpose: Sulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models. Our own work demonstrates that sulforaphane inhibits AR signaling in prostate cancer cells. Here, we report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. Methods: We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≤50 % PSA declines, the primary endpoint. Only one subject experienced a ≤50 % PSA decline. Thus, the primary endpoint was not achieved. Seven patients experienced smaller PSA declines (

Original languageEnglish (US)
Pages (from-to)480-489
Number of pages10
JournalInvestigational New Drugs
Volume33
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Brassica
Prostatic Neoplasms
Vegetables
Diet
Prostate
Clinical Trials
Gene Expression
Food
sulforafan
Incidence
Neoplasms

Keywords

  • Biochemical recurrence
  • Prostate cancer
  • Sulforaphane

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. / Alumkal, Joshi; Slottke, Rachel; Schwartzman, Jacob; Cherala, Ganesh; Munar, Myrna; Graff, Julie; Beer, Tomasz (Tom); Ryan, Christopher; Koop, Dennis; Gibbs, Angela; Gao, Lina; Flamiatos, Jason F.; Tucker, Erin; Kleinschmidt, Richard; Mori, Motomi (Tomi).

In: Investigational New Drugs, Vol. 33, No. 2, 01.04.2015, p. 480-489.

Research output: Contribution to journalArticle

Alumkal, J, Slottke, R, Schwartzman, J, Cherala, G, Munar, M, Graff, J, Beer, TT, Ryan, C, Koop, D, Gibbs, A, Gao, L, Flamiatos, JF, Tucker, E, Kleinschmidt, R & Mori, MT 2015, 'A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer', Investigational New Drugs, vol. 33, no. 2, pp. 480-489. https://doi.org/10.1007/s10637-014-0189-z
Alumkal, Joshi ; Slottke, Rachel ; Schwartzman, Jacob ; Cherala, Ganesh ; Munar, Myrna ; Graff, Julie ; Beer, Tomasz (Tom) ; Ryan, Christopher ; Koop, Dennis ; Gibbs, Angela ; Gao, Lina ; Flamiatos, Jason F. ; Tucker, Erin ; Kleinschmidt, Richard ; Mori, Motomi (Tomi). / A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. In: Investigational New Drugs. 2015 ; Vol. 33, No. 2. pp. 480-489.
@article{2ce2e668f13248b9ae083cda371dd444,
title = "A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer",
abstract = "Introduction: Diets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets also demonstrate modulation of gene expression in important pathways in prostate cells. Purpose: Sulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models. Our own work demonstrates that sulforaphane inhibits AR signaling in prostate cancer cells. Here, we report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. Methods: We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≤50 {\%} PSA declines, the primary endpoint. Only one subject experienced a ≤50 {\%} PSA decline. Thus, the primary endpoint was not achieved. Seven patients experienced smaller PSA declines (",
keywords = "Biochemical recurrence, Prostate cancer, Sulforaphane",
author = "Joshi Alumkal and Rachel Slottke and Jacob Schwartzman and Ganesh Cherala and Myrna Munar and Julie Graff and Beer, {Tomasz (Tom)} and Christopher Ryan and Dennis Koop and Angela Gibbs and Lina Gao and Flamiatos, {Jason F.} and Erin Tucker and Richard Kleinschmidt and Mori, {Motomi (Tomi)}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10637-014-0189-z",
language = "English (US)",
volume = "33",
pages = "480--489",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer

AU - Alumkal, Joshi

AU - Slottke, Rachel

AU - Schwartzman, Jacob

AU - Cherala, Ganesh

AU - Munar, Myrna

AU - Graff, Julie

AU - Beer, Tomasz (Tom)

AU - Ryan, Christopher

AU - Koop, Dennis

AU - Gibbs, Angela

AU - Gao, Lina

AU - Flamiatos, Jason F.

AU - Tucker, Erin

AU - Kleinschmidt, Richard

AU - Mori, Motomi (Tomi)

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Introduction: Diets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets also demonstrate modulation of gene expression in important pathways in prostate cells. Purpose: Sulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models. Our own work demonstrates that sulforaphane inhibits AR signaling in prostate cancer cells. Here, we report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. Methods: We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≤50 % PSA declines, the primary endpoint. Only one subject experienced a ≤50 % PSA decline. Thus, the primary endpoint was not achieved. Seven patients experienced smaller PSA declines (

AB - Introduction: Diets high in cruciferous vegetables are associated with lower risk of incidence of prostate cancer, including aggressive forms of this disease. Human intervention studies with cruciferous vegetable-rich diets also demonstrate modulation of gene expression in important pathways in prostate cells. Purpose: Sulforaphane is a constituent of these foods postulated to harbor the anti-neoplastic activity based on multiple tumor models. Our own work demonstrates that sulforaphane inhibits AR signaling in prostate cancer cells. Here, we report results from the first clinical trial of sulforaphane-rich extracts in men with prostate cancer. Methods: We treated 20 patients who had recurrent prostate cancer with 200 μmoles/day of sulforaphane-rich extracts for a maximum period of 20 weeks and determined the proportion of patients with ≤50 % PSA declines, the primary endpoint. Only one subject experienced a ≤50 % PSA decline. Thus, the primary endpoint was not achieved. Seven patients experienced smaller PSA declines (

KW - Biochemical recurrence

KW - Prostate cancer

KW - Sulforaphane

UR - http://www.scopus.com/inward/record.url?scp=84939538926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939538926&partnerID=8YFLogxK

U2 - 10.1007/s10637-014-0189-z

DO - 10.1007/s10637-014-0189-z

M3 - Article

C2 - 25431127

AN - SCOPUS:84939538926

VL - 33

SP - 480

EP - 489

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -